B2BROKER
26.10.2021 09:02:17 CEST | Business Wire | Press release
B2Broker, a leading technology and liquidity provider in the Forex and Crypto industry, has announced the introduction of a series of outstanding new conditions for its Margin and Crypto Spot liquidity offerings. With today’s announcement comes a new pricing structure that delivers an ultra competitive proposition which is unmatchable in the industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211026005100/en/
B2Broker launched its initial Crypto CFD offering back in 2017, starting with 30 Crypto CFD pairs. The company was the first in this space to implement a Prime Broker business model approach in the Crypto CFD offering. Today, it offers a total of 115 Crypto pairs making it the industry’s leading Crypto CFD provider as well as a tier 1 liquidity provider in the Spot FX, Metals, Equity Indices, Commodities, Single Stocks, and ETFs space all from a single margin account.
To date, B2Broker is used by more than 50% of FX Retail Brokers/Props Houses/Funds, etc, who offer Crypto CFDs and require a main liquidity provider or secondary source of liquidity.
Margin Liquidity
As the popularity of margin trading continues to reach new heights, the new trading conditions from B2Broker will enable its clients to benefit from a whole range of new features and advantages. These include:
New Crypto CFDs
We have added a further 15 new crypto CFDs to our liquidity pool that have proved highly popular recently:
XRP, Cardano, Dogecoin, Solana, Polkadot, Chainlink, Polygon, Uniswap, HIBA INU, Algorand, Avalanche, Terra, Filecoin, Vechain and Maker.
Note: all trade against the USD.
New Margin Requirements
New margin requirements on major crypto CFDs have been decreased from 20% to 10% . This will allow greater opportunities for traders around the world to leverage our unbeatable conditions.
The list of symbols that we have applied changes to include:
BTC/USD, BCH/USD, ETH/USD, LTC/USD, XRP/USD
BTC/EUR, BCH/EUR, ETH/EUR, LTC/EUR, XRP/EUR
BTC/GBP, BCH/GBP, ETH/GBP, LTC/GBP
New Pricing Policy
New commercial offers have been introduced to serve all types of business models. Whether you need a white label solution, a FIX API/gateway connection or an enterprise solution, B2Broker offers a bespoke proposition that serves your business according to your requirements.
Our new Enterprise offering includes PrimeXM or OneZero HUB along with a liquidity solution that gives brokers greater flexibility in terms of managing their liquidity price streams and risk management solutions. The main idea behind this package is to offer broker dealers a solution where they will be able to use our liquidity along with leading HUBs/XCOREs in a more efficient and cost-effective way. For example, if you go directly to PrimeXM or OneZero and buy a Hub with them and then approach B2Broker to buy liquidity, it will prove to be more expensive than simply buying a single Enterprise pack from B2Broker.
The Enterprise liquidity solution is ideal for Brokers who have their own Trading Server such as MT5, MT4, C-Trader etc, and want to be able to manage their price streams, markups, swaps, risk management and more.
New Liquidity Pool Locations
Our liquidity pools are now based in main locations around the world such as LD4, NY4, TY3, SG1 and Mainland China (Beijing). You can choose the best suitable location for your API/Gateway connection.
For our WL clients based in LD4, we have created a global network of access servers which provide the lowest latency connection from any point in the world.
Liquidity Distribution
We offer liquidity distribution across the following platforms to cater for the broad-based demands of our clients PrimeXM, OneZero, FixAPI, MT5, MT4 for FX/CFD, Crypto CFDs etc and B2Trader, Rest API and WEBSocket for Crypto Spot liquidity.
Crypto Spot Liquidity
On the Crypto Spot liquidity side of things, we have introduced a range of outstanding new developments which are applicable to B2BX:
A. Revised ultra-competitive commission ladder which goes down to 0.04%.
B. In total we have enhanced the depth of order book to 100 levels per each side (Buy and Sell) to satisfy the requirements of major players. The compressed order book contains over 120 BTC with an average spread of just $7 USD and market impact of around $140 USD.
C. Increased our trading pairs to consist of additional stable coins and all the top tokens.
B2Broker CEO, Arthur Azizov commented, “We constantly seek to improve our offers and are positioned to offer an unbeatable pricing structure for our services, as well as other favourable conditions which will ultimately benefit our clients. Our liquidity services can be accessed quickly and easily with the most advantageous prices available within the industry and the highest level of technical support”.
B2Broker’s liquidity solutions are used by various types of financial institutions who benefit from our expertise and technology, and our ability to deliver customised liquidity solutions tailored to our clients exact needs. B2Broker offers liquidity on Spot FX, Metals, Commodities, Single Stocks with over 400 instruments, working as a PoP, rather than a market maker. We are therefore on the broker’s side at all times, enabling the best possible liquidity provision in keeping with our clients’ interests.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005100/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom